To address this evidence gap, we assessed the association of OOP costs and initiation of an SGLT2 inhibitor or GLP-1 RA using commercial claims data among adults with T2D and established CVD who are treated with metformin. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.